LiteVax BV founded in 2012, focuses on the development of novel, synthetic adjuvants for a wide range of innovative prophylactic and therapeutic vaccines. These adjuvants may not only increase the efficacy of vaccines, but also lower the dose of vaccine and number of injections needed. Research activities are at the interface between organic chemistry and immunology with strong emphasis on structure-activity relationships.
Area of work
Vaccines, Adjuvants, Immunology, Organic chemistry
The Research & Development facilities are excellent and the presence of expertise and knowledge about pharmaceutical development is a big advantage. By cooperating with other companies at the Park, our research is gaining momentum.